Prognostic factors for overall survival in castration-resistant metastatic prostate cancer treated with docetaxel (MeProCSS): results from a German real-world cohort
International Urology and Nephrology · 27.01.2025 · 57 (7) · 2063-2072
DOI: 10.1007/s11255-025-04389-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Urology and Nephrology, online erschienen am 27.01.2025. Verfasst von Felix Steffens und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology and Urosurgery, Medical Faculty Mannheim, University Medical Centre Mannheim (UMM), University of Heidelberg, Theodor-Kutzer-Uf…. Hauptthemen laut MEDLINE: Docetaxel, Prostatic Neoplasms, Castration-Resistant, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
To identify prognostic factors for overall survival (OS) and develop a prognostic score in patients receiving docetaxel in metastatic castration-resistant prostate cancer (mCRPC).
Methods
Retrospective analysis was conducted on mCRPC patients treated with docetaxel at a German tertiary center between March 2010 and November 2023. Prognostic clinical and laboratory factors were analyzed using uni- and multivariable logistic regression. Next, the result of the modified Glasgow Prognostic Score (mGPS), neutrophil-to-lymphocyte ratio (NLR) (cut-off ≥3), the presence of high-volume bone metastases (as defined by CHAARTED criteria), hemoglobin (Hb) (cut off < 13.2 g/dl), Gleason score ≥8, and presence of visceral metastases were combined into the Metastasized Prostate Cancer Survival Score (MeProCSS). Patients were then stratified into three prognostic groups. Their OS was assessed by Kaplan–Meier analysis.
Results
Median OS for the overall cohort ( n = 153) and the first-line cohort ( n = 83) was 18 and 21.5 months, respectively. In multivariable analysis, high-volume bone metastases and Hb levels below the norm were significant predictors of shorter OS in the total cohort. The MeProCSS demonstrated an area under curve (AUC) of 0.837 in the overall cohort and 0.946 in first-line cohort. Kaplan–Meier analysis revealed a significant association between lower MeProCSS and longer OS in both the overall ( p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology and Urosurgery, Medical Faculty Mannheim, University Medical Centre Mannheim (UMM), University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Baden-Württemberg, Germany.
- Department of Medical Statistics and Biomathematics, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
- Department of Urology and Urosurgery, Medical Faculty Mannheim, University Medical Centre Mannheim (UMM), University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Baden-Württemberg, Germany. manuel.neuberger@…
Zitieren
APA
Steffens, F., Wessels, F., Hetjens, S., Carl, N., Nitschke, K., Uysal, D., Moharam, N., Patroi, P., Worst, T. S., Kowalewski, K. F., Michel, M. S., & Neuberger, M. (2025). Prognostic factors for overall survival in castration-resistant metastatic prostate cancer treated with docetaxel (MeProCSS): results from a German real-world cohort. International Urology and Nephrology, 57(7), 2063-2072. https://doi.org/10.1007/s11255-025-04389-2
Vancouver
Steffens F, Wessels F, Hetjens S, Carl N, Nitschke K, Uysal D, et al. Prognostic factors for overall survival in castration-resistant metastatic prostate cancer treated with docetaxel (MeProCSS): results from a German real-world cohort. International Urology and Nephrology. 2025;57(7):2063-2072. doi:10.1007/s11255-025-04389-2
BibTeX
@article{Steffens2025,
author = {Steffens, Felix and Wessels, Frederik and Hetjens, Svetlana and Carl, Nicolas and Nitschke, Katja and Uysal, Daniel and Moharam, Nadim and Patroi, Paul and Worst, Thomas Stefan and Kowalewski, Karl Friedrich and Michel, Maurice Stephan and Neuberger, Manuel},
title = {Prognostic factors for overall survival in castration-resistant metastatic prostate cancer treated with docetaxel (MeProCSS): results from a German real-world cohort},
journal = {International Urology and Nephrology},
year = {2025},
volume = {57},
number = {7},
pages = {2063--2072},
doi = {10.1007/s11255-025-04389-2}
}
EUVIMED